Human Antibodies - Volume 25, issue 3-4

Article Type: Other

Citation: Human Antibodies, vol. 25, no. 3-4, pp. 71-, 2017

Authors: Steinitz, Michael

Article Type: Other

DOI: 10.3233/HAB-170312

Citation: Human Antibodies, vol. 25, no. 3-4, pp. 73-74, 2017

Authors: Horenstein, Alberto L. | Chillemi, Antonella | Quarona, Valeria | Zito, Andrea | Mariani, Valentina | Faini, Angelo C. | Morandi, Fabio | Schiavoni, Ilaria | Ausiello, Clara Maria | Malavasi, Fabio

Article Type: Research Article

Abstract: This review focuses on the concept of antibodies acting as receptor agonists and antagonists, and on the potential relevance of this notion in applied medicine. Antibodies are composed of three functional units: two antigen-binding fragments (Fabs) that confer antigen specificity and one constant fragment (Fc) linking antibodies to immune effector functions. The proof-of-concept that large amounts of highly specific and homogeneous antibodies could be produced was provided in 1975 by César Milstein and Georges Köhler. These monoclonal antibody (mAb) reagents started a revolution in medical research, diagnostics, and clinical applications. Alongside diagnostic applications, mAbs were successfully used in vivo …: (i) to bind (neutralize/antagonize) antigens expressed on the surface of tumor cells; (ii) to activate immune effector mechanisms; (iii) to crosslink plasma membrane receptors and hence activate therapeutic signaling pathways; and lastly, (iv) the technique was expanded to produce bispecific mAbs, which can bind two different antigens while retaining the ability to activate immune effector functions. The abilities of mAbs to bind, transduce signals, and exert immunostimulatory agonistic capacities are the central issues of this review. The starting point is that some mAbs operate as molecular agonists, substituting for the natural ligand of the receptor. Our analysis is restricted to mAbs that act as receptor agonist/antagonists by either mimicking ligand binding, or through allosteric modulation mediated by binding sites that are topographically distinct from the orthosteric binding site. Functional considerations based on the agonistic stimulation of human CD38 by specific mAbs as surrogate ligands are described as examples of the features of such molecules. Show more

Keywords: Monoclonal antibodies, agonistic, antagonistic, allosteric, biespecific, anti-CD38 antibodies

DOI: 10.3233/HAB-160305

Citation: Human Antibodies, vol. 25, no. 3-4, pp. 75-85, 2017

Authors: Waight, Jeremy D. | Gombos, Randi B. | Wilson, Nicholas S.

Article Type: Research Article

Abstract: Co-stimulatory tumor necrosis factor receptors (TNFRs) can sculpt the responsiveness of T cells recognizing tumor-associated antigens. For this reason, agonist antibodies targeting CD137, CD357, CD134 and CD27 have received considerable attention for their therapeutic utility in enhancing anti-tumor immune responses, particularly in combination with other immuno-modulatory antibodies targeting co-inhibitory pathways in T cells. The design of therapeutic antibodies that optimally engage and activate co-stimulatory TNFRs presents an important challenge of how to promote effective anti-tumor immunity while avoiding serious immune-related adverse events. Here we review our current understanding of the expression, signaling and structural features of CD137, CD357, CD134 and …CD27, and how this may inform the design of pharmacologically active immuno-modulatory antibodies targeting these receptors. This includes the integration of our emerging knowledge of the role of Fcγ receptors (FcγRs) in facilitating antibody-mediated receptor clustering and forward signaling, as well as promoting immune effector cell-mediated activities. Finally, we bring our current preclinical and clinical knowledge of co-stimulatory TNFR antibodies into the context of opportunities for next generation molecules with improved pharmacologic properties. Show more

Keywords: TNFR, TNFRSF, human, antibodies, immunotherapy, oncology, cancer, clinical trials, 4-1BB, CD137, GITR, CD357, OX40, CD134, CD27, FcγR, TRAF, co-stimulation

DOI: 10.3233/HAB-160308

Citation: Human Antibodies, vol. 25, no. 3-4, pp. 87-109, 2017

Authors: Stein, Natan | Tsukerman, Pinchas | Mandelboim, Ofer

Article Type: Research Article

Abstract: One of the most exciting fields in modern medicine is immunotherapy, treatment which looks to harness the power of the immune system to fight disease. A particularly effective strategy uses antibodies designed to influence the activity levels of the immune system. Here we look at two receptors - TIGIT and DNAM-1 - which bind the same ligands but have opposite effects on immune cells, earning them the label `paired receptors'. Importantly, natural killer cells and cytotoxic T cells express both of these receptors, and in certain cases their effector functions are dictated by TIGIT or DNAM-1 signaling. Agonist and antagonist …antibodies targeting either TIGIT or DNAM-1 present many therapeutic options for diseases spanning from cancer to auto-immunity. In this review we present cases in which the modulation of these receptors holds potential for the development of novel therapies. Show more

Keywords: TIGIT, DNAM-1, immunotherapy, cancer, autoimmune disease, NK cells

DOI: 10.3233/HAB-160307

Citation: Human Antibodies, vol. 25, no. 3-4, pp. 111-119, 2017

Authors: Lemus, Hernan Nicolas | Warrington, Arthur E. | Denic, Aleksandar | Wootla, Bharath | Rodriguez, Moses

Article Type: Research Article

Abstract: A single peripheral dose of CNS-binding IgMs promote remyelination and preserve axons in a number of animal models of neurologic disease. A myelin-binding recombinant human IgM (rHIgM22) is presently in a safety trial in MS patients following an acute MS exacerbation. rHIgM22 (directed against oligodendrocytes) or rHIgM12 (directed against neurons) were administered to mice with MOG-induced experimental autoimmune encephalomyelitis (EAE) with study endpoints: clinical deficits and brain and spinal cord pathology. IgMs were administered at a therapeutic dose of 100 μ g intra peritoneal at the time of immunization (day -1, 0, +$1), disease onset (15 days) or peak of …the disease (28 days). Disease course was not worsened by either human IgM regardless of the time of treatment. Of note, the human IgM that recognizes a carbohydrate epitope on gangliosides and NCAM, rHIgM12, reduced brain pathology when given at time of immunization or at onset of disease, but did not reduce clinical deficits or spinal cord disease burden. Hence, treatment with rHIgM12 resulted in marked reduction in meningeal inflammation. Data consistent with the hypothesis that in the EAE model this molecule has an immune-modulatory effect. Treatment with an anti-CD4 blocking IgG prevented both clinical course and CNS pathology. This pre-clinical study further supports the safety of therapeutic CNS-binding human IgMs in the presence of autoimmunity and clearly differentiates them from IgGs directed against MOG or aquaporin-4 that worsen neurologic disease. Show more

Keywords: Human antibody, experimental autoimmune encephalomyelitis, myelin oligodendrocyte glycoprotein, inflammation

DOI: 10.3233/HAB-170313

Citation: Human Antibodies, vol. 25, no. 3-4, pp. 121-129, 2017

Authors: Finke, John M. | Banks, William A.

Article Type: Research Article

Abstract: This review serves to highlight approaches that may improve the access of antibody drugs to regions of the brain affected by Alzheimer's Disease. While previous antibody drugs have been unsuccessful in treating Alzheimer's disease, recent work demonstrates that Alzheimer's pathology can be modified if these drugs can penetrate the brain parenchyma with greater efficacy. Research in antibody blood-brain barrier drug delivery predominantly follows one of three distinct directions: (1) enhancing influx with reduced antibody size, addition of Trojan horse modules, or blood-brain barrier disruption; (2) modulating trancytotic equilibrium and/or kinetics of the neonatal Fc Receptor; and (3) manipulation of antibody …glycan carbohydrate composition. In addition to these topics, recent studies are discussed that reveal a role of glycan sialic acid in suppressing antibody efflux from the brain. Show more

Keywords: Blood-brain barrier, Alzheimer's disease, antibody, IgG, beta-amyloid, FcRn, glycosylation, sialic acid

DOI: 10.3233/HAB-160306

Citation: Human Antibodies, vol. 25, no. 3-4, pp. 131-146, 2017

Authors: Hellstrom, Karl Erik | Dai, Min | Hellstrom, Ingegerd

Article Type: Research Article

Abstract: Over the past several years remarkable therapeutic responses have been obtained with immunomodulatory monoclonal antibodies (mAbs), both in mice \cite{10,18,20,48,54,61} and human cancer patients \cite{1,3,14,28,30,39,80}. However, complete regressions and cures are infrequent and not predictable and some tumor types respond much worse than others. As an attempt to increase curability, we have investigated in mouse models the therapeutic efficacy of several mAb combinations, focusing on anti-PD-1/CTLA-4/CD137 and anti-PD-1/CTLA-4/CD137/CD19, and we have also combined mAbs with the chemotherapeutic drug cisplatin. Our data demonstrate an important contribution of anti-CD19 mAb to therapeutic efficacy, they show that intratumoral delivery of the mAbs is …therapeutically more effective than systemic delivery, and that there is synergy when the mAbs are combined with cisplatin. In an attempt to improve predictability, we developed an in vitro model that may also be employed to search for novel immunomodulatory agents and combinations. This article reviews our data and discusses what is known about the underlying mechanisms. Show more

Keywords: Tumor immunotherapy, immunomodulatory antibody, checkpoint inhibitors, mouse models, immunosuppression, autoimmunity

DOI: 10.3233/HAB-160309

Citation: Human Antibodies, vol. 25, no. 3-4, pp. 147-153, 2017

Article Type: Other

Citation: Human Antibodies, vol. 25, no. 3-4, pp. 155-156, 2017

Article Type: Other

Citation: Human Antibodies, vol. 25, no. 3-4, pp. 157-158, 2017